Stuart Sedlack, G. Yosipovitch, Matthew B. Kerby, Paul C Nagle, S. Ständer
{"title":"美国严重慢性瘙痒的高未满足需求:来自执业社区皮肤科医生的调查结果","authors":"Stuart Sedlack, G. Yosipovitch, Matthew B. Kerby, Paul C Nagle, S. Ständer","doi":"10.1097/itx.0000000000000018","DOIUrl":null,"url":null,"abstract":"Introduction: Chronic pruritus (CP) is a symptom of many diseases, but there is a scarcity of data on this condition in the US. Methods: We surveyed practicing, community-based US dermatologists about aspects of CP, including the number of patients seen annually, patient characteristics, treatments, and level of unmet need. US dermatologists who responded to a screening survey and reported managing ≥10 patients with CP per year were administered a 55-question web-based survey. The survey was conducted from March 27 to April 10, 2015. Results: A total of 212 survey responses were included in the analysis. The prevalence of CP in the dermatologists’ practices in the previous year was reported as 4.8%. Of 9 dermatologic conditions in the survey, CP was rated as having the highest level of unmet need (8.6 on a 10-point scale). Respondents reported that 32.7% of their patients had CP classified as severe/very severe, with 53.7% of patients having CP lasting for >1 year. Most dermatologists prescribed antihistamines (77.5%) or corticosteroids (76.1%) as first-line therapy to their patients with severe/very severe CP, and 36.3% of their patients did not respond to currently available treatments. Discussion: The combined prevalence of CP and its high level of unmet need necessitate the development of effective/tolerable treatments for this patient population.","PeriodicalId":73523,"journal":{"name":"Itch (Philadelphia, Pa.)","volume":"3 1","pages":"e18"},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/itx.0000000000000018","citationCount":"1","resultStr":"{\"title\":\"High unmet need in severe chronic pruritus in the United States: results from a survey of practicing community dermatologists\",\"authors\":\"Stuart Sedlack, G. Yosipovitch, Matthew B. Kerby, Paul C Nagle, S. Ständer\",\"doi\":\"10.1097/itx.0000000000000018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Chronic pruritus (CP) is a symptom of many diseases, but there is a scarcity of data on this condition in the US. Methods: We surveyed practicing, community-based US dermatologists about aspects of CP, including the number of patients seen annually, patient characteristics, treatments, and level of unmet need. US dermatologists who responded to a screening survey and reported managing ≥10 patients with CP per year were administered a 55-question web-based survey. The survey was conducted from March 27 to April 10, 2015. Results: A total of 212 survey responses were included in the analysis. The prevalence of CP in the dermatologists’ practices in the previous year was reported as 4.8%. Of 9 dermatologic conditions in the survey, CP was rated as having the highest level of unmet need (8.6 on a 10-point scale). Respondents reported that 32.7% of their patients had CP classified as severe/very severe, with 53.7% of patients having CP lasting for >1 year. Most dermatologists prescribed antihistamines (77.5%) or corticosteroids (76.1%) as first-line therapy to their patients with severe/very severe CP, and 36.3% of their patients did not respond to currently available treatments. Discussion: The combined prevalence of CP and its high level of unmet need necessitate the development of effective/tolerable treatments for this patient population.\",\"PeriodicalId\":73523,\"journal\":{\"name\":\"Itch (Philadelphia, Pa.)\",\"volume\":\"3 1\",\"pages\":\"e18\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1097/itx.0000000000000018\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Itch (Philadelphia, Pa.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/itx.0000000000000018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Itch (Philadelphia, Pa.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/itx.0000000000000018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
High unmet need in severe chronic pruritus in the United States: results from a survey of practicing community dermatologists
Introduction: Chronic pruritus (CP) is a symptom of many diseases, but there is a scarcity of data on this condition in the US. Methods: We surveyed practicing, community-based US dermatologists about aspects of CP, including the number of patients seen annually, patient characteristics, treatments, and level of unmet need. US dermatologists who responded to a screening survey and reported managing ≥10 patients with CP per year were administered a 55-question web-based survey. The survey was conducted from March 27 to April 10, 2015. Results: A total of 212 survey responses were included in the analysis. The prevalence of CP in the dermatologists’ practices in the previous year was reported as 4.8%. Of 9 dermatologic conditions in the survey, CP was rated as having the highest level of unmet need (8.6 on a 10-point scale). Respondents reported that 32.7% of their patients had CP classified as severe/very severe, with 53.7% of patients having CP lasting for >1 year. Most dermatologists prescribed antihistamines (77.5%) or corticosteroids (76.1%) as first-line therapy to their patients with severe/very severe CP, and 36.3% of their patients did not respond to currently available treatments. Discussion: The combined prevalence of CP and its high level of unmet need necessitate the development of effective/tolerable treatments for this patient population.